Should I buy or sell IRadimed stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares. View IRMD analyst ratings or view top-rated stocks .

What is IRadimed's stock price target for 2024?

1 Wall Street analysts have issued 1-year price objectives for IRadimed's shares. Their IRMD share price targets range from $48.00 to $60.00. On average, they expect the company's share price to reach $54.00 in the next year. This suggests a possible upside of 29.4% from the stock's current price. View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts .

How have IRMD shares performed in 2023?

IRadimed's stock was trading at $28.29 at the start of the year. Since then, IRMD stock has increased by 47.5% and is now trading at $41.73. View the best growth stocks for 2023 here .

Are investors shorting IRadimed?

IRadimed saw a drop in short interest in November. As of November 15th, there was short interest totaling 80,000 shares, a drop of 19.8% from the October 31st total of 99,700 shares. Based on an average daily trading volume, of 33,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.1% of the company's stock are sold short. View IRadimed's Short Interest .

When is IRadimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024. View our IRMD earnings forecast .

How were IRadimed's earnings last quarter?

IRadimed Co. (NASDAQ:IRMD) announced its quarterly earnings data on Friday, November, 3rd. The medical equipment provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.06. The medical equipment provider earned $16.51 million during the quarter, compared to analyst estimates of $16.21 million. IRadimed had a net margin of 25.92% and a trailing twelve-month return on equity of 23.19%.

How often does IRadimed pay dividends? What is the dividend yield for IRadimed?

IRadimed declared a dividend on Monday, February 6th. Stockholders of record on Monday, February 13th will be given a dividend of $1.05 per share on Tuesday, February 21st. This represents a yield of 2.54%. The ex-dividend date is Friday, February 10th. This is a boost from the stock's previous dividend of $1.00. Read our dividend analysis for IRMD .

What ETF holds IRadimed's stock ?

Ballast Small/Mid Cap ETF holds 19,404 shares of IRMD stock, representing 0.98% of its portfolio.

What other stocks do shareholders of IRadimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA) , Gilead Sciences (GILD) , Alphabet (GOOG) , Mastercard (MA) , Micron Technology (MU) , PayPal (PYPL) , CRISPR Therapeutics (CRSP) , IntriCon (IIN) , QUALCOMM (QCOM) and Twitter (TWTR) .

Who are IRadimed's major shareholders?

IRadimed's stock is owned by many different institutional and retail investors. Top institutional investors include RK Capital Management LLC (2.39%), Ranger Investment Management L.P. (1.68%), Northern Trust Corp (0.66%), Rice Hall James & Associates LLC (0.61%), Bank of New York Mellon Corp (0.44%) and Los Angeles Capital Management LLC (0.42%). Insiders that own company stock include Anthony Vuoto , Christopher K Scott , James B Hawkins , Monty K Allen, Monty K Allen and Roger E Susi . View institutional ownership trends .

How do I buy shares of IRadimed?

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

IRadimed Stock Price, News & Analysis (NASDAQ:IRMD)

$41.73

-0.05 (-0.12%)

(As of 12/8/2023 ET)

Compare

Today's Range: $41.25
▼
$42.39
50-Day Range: $37.31
▼
$45.06
52-Week Range: $27.57
▼
$51.04

Volume: 20,929 shs
Average Volume: 26,645 shs
Market Capitalization: $526.22 million

P/E Ratio: 32.35
Dividend Yield: N/A
Price Target: $54.00

IRadimed MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 29.4% Upside
$54.00 Price Target
Short Interest: Healthy
1.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.59
Based on 2 Articles This Week
Insider Trading: Selling Shares
$1.76 M Sold Last Quarter
Proj. Earnings Growth: 19.12%
From $1.36 to $1.62 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.26 out of 5 stars

Medical Sector

11th out of 932 stocks

Surgical & Medical Instruments Industry

4th out of 93 stocks

3.5

Analyst's Opinion

Consensus Rating
IRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $54.00, IRadimed has a forecasted upside of 29.4% from its current price of $41.73.
Amount of Analyst Coverage
IRadimed has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.05% of the float of IRadimed has been sold short.
Short Interest Ratio / Days to Cover
IRadimed has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IRadimed has recently decreased by 19.76%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
IRadimed does not currently pay a dividend.
Dividend Growth
IRadimed does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IRadimed has received a 67.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Real-time vital parameter monitors for MRI machines", "Intravenous therapy equipment for MRI machines", and "ECG monitors" products. See details.
Environmental Sustainability
The Environmental Impact score for IRadimed is -0.85.

3.1

News and Social Media Coverage

News Sentiment
IRadimed has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for IRadimed this week, compared to 1 article on an average week.
Search Interest
7 people have searched for IRMD on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added IRadimed to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,756,432.00 in company stock.
Percentage Held by Insiders
42.60% of the stock of IRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
48.61% of the stock of IRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for IRadimed are expected to grow by 19.12% in the coming year, from $1.36 to $1.62 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IRadimed is 32.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 115.28.
Price to Earnings Ratio vs. Sector
The P/E ratio of IRadimed is 32.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.14.
Price to Book Value per Share Ratio
IRadimed has a P/B Ratio of 7.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IRadimed Stock (NASDAQ:IRMD)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

IRMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IRMD Stock News Headlines

December 6, 2023 | finance.yahoo.com

Why We Like The Returns At IRadimed (NASDAQ:IRMD)

December 6, 2023 | finance.yahoo.com

Insider Sell Alert: Director James Hawkins Sells Shares of iRadimed Corp (IRMD)

December 10, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 30, 2023 | finance.yahoo.com

IRADIMED CORPORATION Named a 2024 Most Successful Small-Cap Company in America by Forbes

November 18, 2023 | morningstar.com

iRadimed Corp IRMD

November 17, 2023 | finance.yahoo.com

5 Small Hidden Gems for the Rest of 2023

November 14, 2023 | finance.yahoo.com

Insider Sell: Director Anthony Vuoto Sells 3,055 Shares of iRadimed Corp (IRMD)

November 6, 2023 | seekingalpha.com

IRadimed: Which Way Now

December 10, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 5, 2023 | finance.yahoo.com

IRadimed Corporation (NASDAQ:IRMD) Q3 2023 Earnings Call Transcript

November 3, 2023 | finanznachrichten.de

iRadimed Corporation: IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results

November 3, 2023 | chron.com

IRadimed: Q3 Earnings Snapshot

November 3, 2023 | finance.yahoo.com

IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results

November 3, 2023 | finance.yahoo.com

iRadimed Corp (IRMD) Reports 23% YoY Revenue Growth for Q3 2023

November 2, 2023 | benzinga.com

iRadimed's Earnings: A Preview

November 2, 2023 | markets.businessinsider.com

Here's what to expect from iRadimed's earnings report

October 26, 2023 | finance.yahoo.com

IRADIMED CORPORATION to Hold 2023 Third Quarter Financial Results Conference Call on November 3rd

October 23, 2023 | finance.yahoo.com

IRadimed Corporation's (NASDAQ:IRMD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

October 5, 2023 | finance.yahoo.com

IRadimed's (NASDAQ:IRMD) investors will be pleased with their splendid 113% return over the last three years

September 23, 2023 | money.usnews.com

Iradimed Corp

September 22, 2023 | msn.com

4 Top Profitable Stocks to Invest in Using Net Income Ratio

September 13, 2023 | finance.yahoo.com

Insider Sell: Roger Susi Sells 10,000 Shares of iRadimed Corp (IRMD)

September 6, 2023 | finance.yahoo.com

IRADIMED CORPORATION to Participate at Upcoming Investor Conferences

September 4, 2023 | finance.yahoo.com

With a 41% stake, IRadimed Corporation (NASDAQ:IRMD) insiders have a lot riding on the company

August 31, 2023 | msn.com

Iradimed (IRMD) Price Target Increased by 6.21% to 58.14

August 25, 2023 | msn.com

IRadimed Continues Ploughing Along With Superb Economic Characteristics

August 24, 2023 | finance.yahoo.com

Zacks.com featured highlights Perdoceo Education, Boot Barn and iRadimed

See More Headlines

Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRadimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/01/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IRMD
CUSIP: N/A
CIK: 1325618
Web: www.iradimed.com
Phone: (407) 677-8022
Fax: 407-677-5037
Employees: 123
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $54.00
High Stock Price Target: $60.00
Low Stock Price Target: $48.00
Potential Upside/Downside: +29.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.29
Trailing P/E Ratio: 32.35
Forward P/E Ratio: 30.68
P/E Growth: N/A
Net Income: $12.83 million
Net Margins: 25.92%
Pretax Margin: 32.97%
Return on Equity: 23.19%
Return on Assets: 19.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.13
Quick Ratio: 7.65

Sales & Book Value

Annual Sales: $53.30 million
Price / Sales: 9.87
Cash Flow: $1.07 per share
Price / Cash Flow: 38.90
Book Value: $5.86 per share
Price / Book: 7.12

Miscellaneous

Outstanding Shares: 12,610,000
Free Float: 7,238,000
Market Cap: $526.22 million
Optionable: Not Optionable
Beta: 0.87

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Roger E. Susi (Age 70)
Founder, Chairman, CEO & President
Comp: $586.04k
Mr. John F. Glenn (Age 61)
CFO & Corporate Secretary
Comp: $411.79k
Mr. Randy Waddell
Vice President of Worldwide Sales & Marketing
Mr. Steve Kachelmeyer
Vice President of Regulatory Affairs & Quality Assurance
Mr. Lynn Neuhardt
Vice President of Research & Development
Mr. Chris Williamson
Executive Vice President of Continuous Improvement & Information Technology
Mr. Matt Garner
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell IRadimed stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares.
View IRMD analyst ratings or view top-rated stocks.
What is IRadimed's stock price target for 2024?: 1 Wall Street analysts have issued 1-year price objectives for IRadimed's shares. Their IRMD share price targets range from $48.00 to $60.00. On average, they expect the company's share price to reach $54.00 in the next year. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts.
How have IRMD shares performed in 2023?: IRadimed's stock was trading at $28.29 at the start of the year. Since then, IRMD stock has increased by 47.5% and is now trading at $41.73.
View the best growth stocks for 2023 here.
Are investors shorting IRadimed?: IRadimed saw a drop in short interest in November. As of November 15th, there was short interest totaling 80,000 shares, a drop of 19.8% from the October 31st total of 99,700 shares. Based on an average daily trading volume, of 33,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.1% of the company's stock are sold short.
View IRadimed's Short Interest.
When is IRadimed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our IRMD earnings forecast.
How were IRadimed's earnings last quarter?: IRadimed Co. (NASDAQ:IRMD) announced its quarterly earnings data on Friday, November, 3rd. The medical equipment provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.06. The medical equipment provider earned $16.51 million during the quarter, compared to analyst estimates of $16.21 million. IRadimed had a net margin of 25.92% and a trailing twelve-month return on equity of 23.19%.

How often does IRadimed pay dividends? What is the dividend yield for IRadimed?: IRadimed declared a dividend on Monday, February 6th. Stockholders of record on Monday, February 13th will be given a dividend of $1.05 per share on Tuesday, February 21st. This represents a yield of 2.54%. The ex-dividend date is Friday, February 10th. This is a boost from the stock's previous dividend of $1.00.
Read our dividend analysis for IRMD.
What ETF holds IRadimed's stock ?: Ballast Small/Mid Cap ETF holds 19,404 shares of IRMD stock, representing 0.98% of its portfolio.
What other stocks do shareholders of IRadimed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).
Who are IRadimed's major shareholders?: IRadimed's stock is owned by many different institutional and retail investors. Top institutional investors include RK Capital Management LLC (2.39%), Ranger Investment Management L.P. (1.68%), Northern Trust Corp (0.66%), Rice Hall James & Associates LLC (0.61%), Bank of New York Mellon Corp (0.44%) and Los Angeles Capital Management LLC (0.42%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi.
View institutional ownership trends.
How do I buy shares of IRadimed?: Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IRMD) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial